Your browser doesn't support javascript.
loading
Combined Haploidentical Hematopoetic Stem Cell Transplantation and Liver Transplantation in a Pediatric Patient.
Uygun, Vedat; Aliosmanoglu, Ibrahim; Daloglu, Hayriye; Öztürkmen, Seda; Yalçin, Koray; Karasu, Gülsün; Yesilipek, Akif.
Afiliación
  • Uygun V; Istinye University, Faculty of Medicine, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey.
  • Aliosmanoglu I; Istinye University, Faculty of Medicine, MedicalPark Antalya Hospital, Department of General Surgery, Antalya, Turkey.
  • Daloglu H; Antalya Bilim University, Faculty of Health Sciences, MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey.
  • Öztürkmen S; MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey.
  • Yalçin K; Bahçesehir University, Faculty of Medicine, MedicalPark Göztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Istanbul, Turkey.
  • Karasu G; MedicalPark Göztepe Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Istanbul, Turkey.
  • Yesilipek A; MedicalPark Antalya Hospital, Department of Pediatric Bone Marrow Transplantation Unit, Antalya, Turkey.
Int J Hematol Oncol Stem Cell Res ; 17(4): 291-295, 2023 Oct 01.
Article en En | MEDLINE | ID: mdl-38076781
ABSTRACT
Solid organ transplantation from the same donor is an established procedure for end-stage organ failure that developed after a previous hematopoietic stem cell transplantation (HSCT); however, it is rarely done in patients transplanted with unmanipulated haplo-HSCT. There are no pediatric reports regarding the long-term performance of organ transplantation after haplo-HSCT with post-transplant cyclophosphamide (PTCY). A juvenile myelomonocytic leukemia patient, who underwent unmanipulated haplo-HSCT with PTCY from her mother at the age of 3 years, developed chronic liver graft versus host disease (GvHD) which was refractory to specific GvHD treatment. Liver transplantation (LT) from her mother (the donor of her haplo-HSCT) was decided as the next line of treatment. LT was performed on day 540 post-HSCT, and the donor's left lateral segment was appropriately removed and attached to the recipient. The symptoms of GvHD completely regressed in a month. The patient died on day 121 after LT, because of a possible hepato-pulmonary syndrome. Organ failure can develop after allo-HSCT secondary to GvHD and therefore performing HSCT from a haplo-donor may be superior to a matched unrelated donor in terms of subsequent organ transplantation for organ failure.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Hematol Oncol Stem Cell Res Año: 2023 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Hematol Oncol Stem Cell Res Año: 2023 Tipo del documento: Article País de afiliación: Turquía